The purpose of the current study was to evaluate the characteristics of borderline ovarian tumors (BOTs) diagnosed during pregnancy.
(P = 0.01). Only two patients had an initial complete staging. BOTs were mucinous, serous and mixed in 48%, 42% and 10% of patients, respectively. Twenty-one percent of mucinous BOTs exhibited intraepithelial carcinoma or microinvasion. Forty-seven percent of serous BOTs exhibited micropapillary features, noninvasive implants or microinvasion. Restaging surgery performed in 52% patients resulted in upstaging in 24% of cases. Recurrence rate in patients with serous BOT with micropapillary features or peritoneal implants was 7.5%.
Conclusions: BOTs diagnosed during pregnancy exhibit a high incidence of aggressive features and are rarely completely staged initially. Given this setting, up-front salpingo-oophorectomy should be considered and restaging planned.
Key words: borderline ovarian tumors, mucinous borderline ovarian tumors, pregnancy, restaging surgery, serous micropapillary borderline ovarian tumors introduction Borderline ovarian tumors (BOTs) were defined as a distinct histological entity by the International Federation of Gynecology and Obstetrics (FIGO) [1] and the World Health Organization (WHO) [2] in the early 1970s. They account for 10%-20% of all ovarian epithelial tumors [3, 4] .
Although one third of BOTs are diagnosed in women of childbearing age-<40 years [5] -and sonography is systematically performed during pregnancy, little is known about the incidence and the management of BOTs incidentally diagnosed during pregnancy. To date, literature on BOTs diagnosed during pregnancy consists of case reports only which means there is a lack of published clinical data to establish a therapeutic strategy in this setting.
The aims of this French multicenter retrospective study were therefore to evaluate the characteristics of BOTs diagnosed during pregnancy and to determine a therapeutic strategy.
materials and methods
From January 2009 to December 2009, we conducted a retrospective multicenter study of 40 patients with BOTs diagnosed during pregnancy and treated between 1997 and 2009 at one of six institutions (one cancer center and five tertiary universitary departments of Gynecology and Obstetrics) in France. The protocol was approved by the Ethics Committee of the Collège National des Gynécologues et Obstétriciens Franc xais (CNGOF).
The medical records were reviewed to determine age, gestational age, tumor stage, histology, tumor size, surgical procedure, intra-and postoperative complications and the final histological status. Outcome was obtained from the outpatient records.
Histologic typing was performed essentially according to the recommendations of the 2003 WHO classification schemata [6] . The histological criteria used for the diagnosis of borderline tumors included: (i) stratification of the epithelial lining of the papillae, with formation of microscopic papillary projections or tufts arising from the epithelial lining of the papillae; (ii) nuclear atypia; (iii) mitotic activity; (iv) intracystic clusters of free-floating cells and (v) absence of stromal invasion. Patients with serous BOTs exhibiting micropapillary features and patients with mucinous BOTs exhibiting features of intraepithelial carcinoma were also included as were patients with microinvasion. No central pathology review was performed.
Surgical treatment was considered to be conservative if at least a portion of one ovary and the uterus were conserved. Conservative ovarian treatment consisted of unilateral cystectomy, unilateral salpingooophorectomy (USO), USO and contralateral cystectomy or bilateral cystectomy. Surgical treatment was considered radical when bilateral salpingo-oophorectomy was performed. In addition to this conservative or radical surgery, staging was considered complete only if all peritoneal surfaces had been carefully inspected and if peritoneal washing, multiple random or oriented biopsies and infracolonic omentectomy had been performed. Systematic appendectomy was an additional criterion for complete staging for mucinous BOTs. Initial staging surgery was considered to be incomplete in all other cases regardless of the radical or conservative nature of treatment. Dissection of the pelvic and retroperitoneal lymph nodes was not required for complete staging as this procedure was abandoned in 1995 as part of the systematic staging of BOTs.
Disease staging was performed according to the recommendations of FIGO [7] . A restaging operation was defined as a surgical procedure performed after an initial incomplete staging regardless of the initial disease stage, such that (i) the interval between initial surgery and restaging was <6 months and (ii) the patient had not received adjuvant therapy. The restaging procedure involved either laparotomy or laparoscopy depending on the participating centers.
Statistical analysis was performed using the chi-square test and the Student's t-test. P values <0.05 were considered significant.
results
Patient characteristics and diagnostic circumstances of BOT during pregnancy are resumed in Table 1 . The mean age at diagnosis was 30.2 6 5.4 years (range: 20-42). Nineteen women were nulliparous and two had a history of infertility. One patient had a prior unilateral cystectomy and contralateral adnexectomy for bilateral serous BOTs with noninvasive implants (case 1).
BOTs were mainly diagnosed during the first trimester of pregnancy (62%; N = 25). The diagnostic circumstances for these patients were pain in 4 cases (16%), systematic sonography in 17 cases (68%) and systematic clinical examination in 4 cases (16%). The diagnostic circumstances for the 10 (25%) BOTs diagnosed during the second trimester of pregnancy were pain in 6 cases (60%), systematic sonography in 3 (30%) and systematic clinical examination in 1 (10%). Five BOTs (12%) were diagnosed during the third trimester of pregnancy including one during systematic sonography and the remaining four during cesarean section. Among the 21 ovarian tumors detected by systematic sonography, the borderline nature was suggested in two cases.
Serum levels of the tumoral markers CA-125 and CA 19.9 were available in 17 and 8 cases, respectively. Mean serum value of CA-125 was 91 6 124 UI/ml and was abnormal (>35 UI/ml) in seven patients (41%) (four with mucinous BOT and three with serous BOT). Mean serum value of CA19.9 was 11 6 8 UI/ml and was always normal.
Thirty-six patients underwent surgery during pregnancy; 10 during the first trimester, 22 during the second and four during cesarean section. Four patients underwent surgery in the postpartum period (Table 1) .
Laparotomy was performed in 25 cases (62.5%) including 4 cases of cesarean section. Laparoscopy was performed in 15 cases (37.5%). Conversion to open surgery was required in five cases for tumor size (33.3%). Laparoscopy was more frequently performed during the first trimester of pregnancy and laparotomy more frequently performed during the second (P = 0.01).
Salpingo-oophorectomy (N = 24) was more frequently performed than cystectomy (N = 11) during pregnancy (P = 0.01). Peritoneal washing was performed in 29 patients (72.5%). Peritoneal biopsies, omentectomy and appendectomy were performed in 11 (27.5%), 3 (7.5%) and 2 patients (5%), respectively. Two patients (5%) had an initial complete staging.
Thirty-two patients (80%) delivered at term and two (5%) during the 7th month of pregnancy for obstetrical conditions (preeclampsia). Three patients had a miscarriage; one during the first trimester and two during the second. Two patients underwent legal termination. One patient was lost to follow-up. The median tumor size was 12.1 6 7 cm (range: 1.5-30) and not significantly different according to the term of pregnancy at the time of diagnosis.
Intraoperative histology was performed in 13 patients (32.5%) resulting in a diagnosis of BOT in 8 cases (61.5%) and benign tumor in 5 (38.5%). Among these five tumors diagnosed as benign by intraoperative histology, definitive histology found four mucinous BOT including one with microinvasion and one serous BOT with micropapillary patterns. Among the eight tumors diagnosed by intraoperative histology as BOT, definitive histology found two mucinous BOT with microinvasion and one serous BOT with micropapillary patterns.
BOTs were mucinous in 19 patients (48%), serous in 17 patients (42%) and mixed (sero-mucinous or mucinous and endometrioid) in 4 (10%) ( Table 2) .
Mucinous BOTs exhibited intraepithelial carcinoma or microinvasion in four cases (21%). Serous BOTs exhibited micropapillary feature (Figure 1 ) or noninvasive implants (Figure 2 ) or microinvasion in eight cases (47%). Mixed BOTs exhibited micropapillary, intraepithelial carcinoma and noninvasive implants in one case each. original articles
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Initial FIGO stages were IA in 31 patients (77.5%), IB in 2 (5%), IC in 2 (5%), II in 3 (7.5%) and III in 2 patients (5%).
The mean follow-up was 37.5 6 38.9 months. Restaging surgery was performed in 21 patients (52%); in 2 during pregnancy, in 5 during cesarean section and in 14 during the postpartum period (Table 3) . Radical and conservative surgery was performed during restaging operation in 4 and 17 patients, respectively.
Sixteen of the 21 patients who underwent restaging surgery had a complete staging. Five of these were subsequently upstaged: three serous BOT (one with micropapillary pattern), one mucinous BOT and one sero-mucinous BOT with noninvasive implants. Four of them were upstaged due to the presence of peritoneal implants and one due to contralateral mucinous BOTs with positive cytology. Moreover, micropapillary features and microinvasion were detected after salpingo-oophorectomy in two patients who had cystectomy at initial surgery.
Recurrence occurred in three patients (7.5%). Two of these had serous BOTs associated with micropapillary features and peritoneal implants and relapsed on the contralateral ovary with the same histology. The last recurrence was observed in a patient with a serous BOT on the ipsilateral ovary after initial cystectomy and exhibited micropapillary features at recurrence. The frequency of recurrence in patients who underwent restaging was 4.7% and in those who did not 10.5% (not significant).
No invasive cancer was observed during the study period.
discussion
The present study demonstrates that BOTs detected during pregnancy have specific characteristics with a high frequency of advanced stage and patterns of aggressiveness. This multicenter study was the first large series focusing on the diagnosis and management of BOTs detected during pregnancy. Although pregnancy is a specific condition allowing detection of adnexal masses because of the systematic use of Annals of Oncology original articles sonography, the exact incidence of BOTs diagnosed during pregnancy remains unknown. Previous studies in pregnant patients with adnexal masses have reported an incidence of BOTs ranging from 0% to 8% [8] [9] [10] [11] . In the current study, the majority of BOTs were diagnosed by sonography or clinical examination during the first trimester of the pregnancy. Except for four patients, all the BOTs were treated during pregnancy and less than one-quarter operated on only by laparoscopy. Only two patients had complete initial staging. These results are partly in agreement with those of previous studies on the management of BOTs showing both a low incidence of laparoscopic management and a low rate of initial complete staging [12] [13] [14] [15] [16] [17] . This could be explained by large tumor size and difficulties to perform laparoscopy especially in patients during the second and a fortiori during the third trimester of pregnancy. However, even for patients treated first by laparotomy, only two stagings were complete which could be explained by the absence of preoperative assessment of the borderline nature of the ovarian tumors and the low request for intraoperative histology.
In the current study, $20% of patients had final stage II to III BOTs. This high incidence of advanced stages of BOT contrasts with previous studies showing that $90% of BOTs are diagnosed at stage I in nonpregnant women [18] . Histologic typing of BOTs from the pregnant patients in our study also revealed a high incidence (48%) of mucinous BOTs of which 21% with features of aggressiveness including intraepithelial carcinoma and microinvasion. This contrasts with previous studies showing that serous BOTs represented $55% and mucinous BOTs $30% of all BOT in nonpregnant patients [14, 19] . Another characteristic of BOTs diagnosed during pregnancy is the high incidence of serous BOTs with aggressive patterns. Indeed, in our study, micropapillary features were noted in 41.2% of serous BOTs. This is of particular relevance as previous studies [4, [20] [21] [22] have underlined that serous BOTs exhibiting micropapillary features were more frequently bilateral and with invasive implants compared with those without. Moreover, recent molecular data comparing RNA from epithelial cells of serous BOT, serous BOT with micropapillary patterns and low grade serous carcinoma (LGSC) found that gene expression profile of serous BOT with micropapillary patterns is similar to LGSC but distinct from serous BOT with candidates genes involved in the mitogenactivated protein kinase pathway [23] . Despite these data, true prognostic value of micropapillary patterns remains a matter of debate [24] . Indeed, decreased survival of patients with micropapillary patterns is linked to the increased rate of invasive peritoneal implants, while micropapillary architecture per se seems to have no impact on overall survival when controlled for peritoneal implants [25, 26] . Our results are in accordance with those of Mooney et al. [27] showing, in a series of 10 BOT diagnosed during pregnancy, a high proportion of microinvasion and implants in serous BOT. In addition to age at diagnosis, elevated preoperative CA-125 and invasive implants, Shih et al. [22] noted that micropapillary histology was also a risk factor for recurrence. In our study, the three recurrences showed micropapillary features. Finally, our high proportion of patients with mucinous and serous BOTs exhibiting features of aggressiveness (peritoneal implants, microinvasion, intraepithelial carcinoma and micropapillary features) justifies an initial salpingo-oophorectomy in pregnant patients with unilateral BOT.
From the pathological viewpoint, previous studies have underlined that estrogens have been shown to stimulate cell proliferation in cells containing the estrogen receptor (ER) [28] [29] [30] [31] . Lindgren et al. [32] demonstrated a simultaneous expression of ERa, ERb and progesterone receptor (PR) in epithelial cells of all ovarian tumor types, except for mucinous tumors, independently of histological subtypes, i.e. benign, borderline or malignant. Moreover, these authors found a decreased ERa/ERb ratio in ovarian epithelial cells of malignant tumors, including serous BOTs, compare to normal ovarian tissue. Finally, the Ki67 index (a nuclear antigen related to cell proliferation) [33] was inversely correlated to PR and ERb expression potentially explaining the development of BOTs associated with pregnancy.
Restaging surgery is particularly questionable due to the low incidence of upstaging and the absence of its impact of both recurrence rate and survival [13, 17, 34] . Indeed, in a French multicenter study, only 14.8% of the 54 patients undergoing a restaging operation were upstaged [13] . Moreover, upstaging was more frequent in patients with serous BOTs and those who had had a cystectomy. In our study, although two-thirds of our patients had a salpingo-oophorectomy during the first operation, only two patients underwent a complete initial staging. Among the 21 patients undergoing a restaging operation, 5 were upstaged (24%). This rate is higher than those previously reported in large series of restaging operations in patients with BOTs diagnosed in nonpregnant patients (from 12.3% to 14.8%) [13, 34] . This apparent discrepancy is explained by the high rate of patients with advanced stage of BOT, with BOTs exhibiting micropapillary features, with intraepithelial carcinoma, microinvasion and peritoneal implants. Despite the small sample size and in contrast to BOTs diagnosed in nonpregnant patients, our results suggest that patients with a BOT diagnosed during pregnancy might benefit from restaging. Moreover, when a cesarean section is required for obstetrical conditions after initial surgery detecting a BOT, patients should be informed about the possibility of requiring a restaging operation including at least a peritoneal washing, careful exploration of the peritoneal cavity, peritoneal biopsies, omentectomy and appendectomy in the case of mucinous BOT.
Some limitations of the current study have to be underlined. First, the retrospective nature of the study cannot avoid bias. Second, due to difficulties to assess the borderline nature of ovarian tumor by sonography and the relative contraindication of gadolinium injection for magnetic resonance imaging during pregnancy, it is difficult to draw definitive conclusions on surgical management of ovarian tumor during pregnancy. However, for complex or indeterminated adnexal masses, it seems legitimate to recommend both a first salpingooophorectomy to avoid peritoneal dissemination and a systematic intraoperative histology. Third, although there was a high rate of restaging surgery, no predictive factors of upstaging were significantly identified due to the sample size. Finally, in addition to classic histological criteria, further biological studies are required to determine whether different original articles Annals of Oncology pathways might exist between BOTs in pregnant or nonpregnant patients.
In conclusion, our results support that BOTs diagnosed during pregnancy have different clinical and histological characteristics to those diagnosed in nonpregnant patients. Due to the high incidence of pregnant patients with BOTs exhibiting features of aggressiveness and the frequent incomplete initial staging, surgeons should consider up-front salpingo-oophorectomy and routinely schedule a restaging operation in these patients.
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